AbbVie/Allergan Merger Edges Closer To FTC Clearance

AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.

divestment words on blue road sign with blurred background
Allergan divests two products to win FTC support of merger with AbbVie.

Another big merger has moved closer to approval from the US Federal Trade Commission as Allergan PLC announced agreements to divest its pipeline drug brazikumab and its commercial product Zenpep (pancrelipase) in order to be acquired by AbbVie Inc.

The companies announced on 27 January that AstraZeneca PLC will acquire the IL-23 inhibitor brazikumab, in Phase IIb/III for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet